[HTML][HTML] Sofosbuvir: a novel oral agent for chronic hepatitis C
E Cholongitas, GV Papatheodoridis - Annals of Gastroenterology …, 2014 - ncbi.nlm.nih.gov
Major changes have emerged during the last few years in the therapy of patients with
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
Sofosbuvir: a novel oral agent for chronic hepatitis C
E Cholongitas, GV Papatheodoridis - Annals of Gastroenterology, 2014 - 172.104.143.169
Major changes have emerged during the last few years in the therapy of patients with
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
[PDF][PDF] Sofosbuvir: a novel oral agent for chronic hepatitis C
E Cholongitasa… - Annals of …, 2014 - pdfs.semanticscholar.org
Major changes have emerged during the last few years in the therapy of patients with
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
[引用][C] Sofosbuvir: a novel oral agent for chronic hepatitis C
E Cholongitas - Ann Gastroenterol, 2014 - cir.nii.ac.jp
Sofosbuvir: a novel oral agent for chronic hepatitis C | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
[HTML][HTML] Sofosbuvir: a novel oral agent for chronic hepatitis C.
E Cholongitas, GV Papatheodoridis - Annals of Gastroenterology, 2014 - europepmc.org
Major changes have emerged during the last few years in the therapy of patients with
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
[PDF][PDF] Sofosbuvir: a novel oral agent for chronic hepatitis C
E Cholongitasa… - Annals of …, 2014 - scienceopen.com
Major changes have emerged during the last few years in the therapy of patients with
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
Sofosbuvir: a novel oral agent for chronic hepatitis C
E Cholongitas, GV Papatheodoridis - Annals of Gastroenterology, 2014 - annalsgastro.gr
Major changes have emerged during the last few years in the therapy of patients with
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
Sofosbuvir: a novel oral agent for chronic hepatitis C
E Cholongitas, GV Papatheodoridis - Annals of Gastroenterology, 2014 - annalsgastro.gr
Major changes have emerged during the last few years in the therapy of patients with
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
Sofosbuvir: a novel oral agent for chronic hepatitis C.
E Cholongitas… - Annals of …, 2014 - search.ebscohost.com
Major changes have emerged during the last few years in the therapy of patients with
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
[PDF][PDF] Sofosbuvir: a novel oral agent for chronic hepatitis C
E Cholongitasa, GV Papatheodoridisb - Annals of Gastroenterology, 2014 - Citeseer
Major changes have emerged during the last few years in the therapy of patients with
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …